Supplementary Materials

Supplementary Material for:

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders, Alexander J. Bankovich, Wade C. Anderson, Monette A. Aujay, Sheila Bheddah, KristenAnn Black, Radhika Desai, Paul A. Escarpe, Johannes Hampl, Amy Laysang, David Liu, Javier Lopez-Molina, Milly Milton, Albert Park, Marybeth A. Pysz, Hui Shao, Brian Slingerland, Michael Torgov, Samuel A. Williams, Orit Foord, Philip Howard, Jacek Jassem, Andrzej Badzio, Piotr Czapiewski, David H. Harpole, Afshin Dowlati, Pierre P. Massion, William D. Travis, M. Catherine Pietanza, J. T. Poirier, Charles M. Rudin, Robert A. Stull, Scott J. Dylla*

*Corresponding author. E-mail: scott.dylla{at}

Published 26 August 2015, Sci. Transl. Med. 7, 302ra136 (2015)
DOI: 10.1126/scitranslmed.aac9459

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Elevated expression of DLL3 mRNA in SCLC.
  • Fig. S2. Specificity of anti-DLL3 IHC antibody.
  • Fig. S3. DLL3 protein expression by IHC in representative samples from tissue microarrays.
  • Fig. S4. In vitro plasma stability of SC16LD6.5.
  • Fig. S5. Enumeration of cells with localization of human antibody in the late endosome.
  • Fig. S6. DLL3 knockdown confirmation by flow cytometry.
  • Fig. S7. In vivo efficacy of SC16LD6.5, naked SC16 antibody, and free toxin, D6.5.
  • Fig. S8. In vivo tolerability of SC16LD6.5.
  • Fig. S9. Elimination of TICs by SC16LD6.5.
  • Fig. S10. Off-target toxicities observed in nonhuman primates.
  • Table S1. DLL3 normal tissue expression.
  • Table S2. DLL3 microarray expression in PDX.
  • Table S3. Biacore affinity characterization of SC16 and SC16LD6.5 binding to human, cyno, and rat DLL3.
  • Table S4. LU64 TIC frequency determination.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5. DLL3 whole transcriptome metrics (provided as an Excel file).